IP Library › Granted Patent US 8,987,202
Granted Patent B2
US 8,987,202 · App. 11/424,035 · Granted Mar 24, 2015

Factor VII or Factor VIIa Gla domain variants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,987,202
App. No.
11/424,035
Granted
Mar 24, 2015
Kind
B2
Abstract

Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence shown in SEQ ID NO:1, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

Claims (31)

1. A method for treating a mammal having a disease or a disorder wherein clot formation is desirable, comprising administering to a mammal in need thereof an effective amount of a recombinant Factor VII (FVII) or Factor VIIa (FVIIa) polypeptide variant having clotting activity, said recombinant FVII or FVIIa polypeptide variant having at least 95% sequence identity to SEQ ID NO: 1, wherein the arginine residue at position 36 is substituted with a negatively charged amino acid residue, and wherein said disease or disorder is selected from the group consisting of hemorrhages, variceal bleeding, and hemophilia.

2. The method of claim 1 , wherein said disease or disorder is hemophilia.

3. A method for treating intracerebral haemorrhage or traumatic brain injury, comprising administering to a patient in need thereof an effective amount of a recombinant Factor VII (FVII) or Factor VIIa (FVIIa) polypeptide variant having clotting activity, said recombinant FVII or FVIIa polypeptide variant having at least 95% sequence identity to SEQ ID NO: 1, wherein the arginine residue at position 36 is substituted with a negatively charged amino acid residue, and wherein amino acid positions of the variant are numbered relative to the amino acid sequence of SEQ ID NO: 1.

4. The method of claim 1 , wherein the amino acid substitution in position 36 is R36D or R36E.

5. The method of claim 4 , wherein the amino acid substitution in position 36 is R36E.

6. The method of claim 1 , wherein the recombinant FVII or FVIIa polypeptide variant comprises an amino acid substitution in position 34.

7. The method of claim 6 , wherein a negatively charged amino acid residue is substituted for the alanine residue in position 34 of the variant.

8. The method of claim 7 , wherein the amino acid substitution in position 34 is A34E.

9. The method of claim 7 , wherein the amino acid substitution in position 36 is R36E or R36D.

10. The method of claim 8 , wherein the recombinant FVII or FVIIa polypeptide variant comprises the amino acid substitutions A34E+R36E or A34E+R36D.

11. The method of claim 10 , wherein the recombinant FVII or FVIIa polypeptide variant comprises the amino acid substitutions A34E+R36E.

12. The method of claim 4 , wherein the recombinant FVII or FVIIa polypeptide variant comprises an amino acid substitution in position 10 or 32.

13. The method of claim 12 , wherein the recombinant FVII or FVIIa polypeptide variant comprises amino acid substitutions in positions 10 and 32.

14. The method of claim 13 , wherein the amino acid substitution in position 32 is K32E.

15. The method of claim 14 , wherein the amino acid substitution in position 10 is P10Q.

16. The method of claim 15 , wherein the recombinant FVII or FVIIa polypeptide variant comprises the amino acid substitutions P10Q+K32E+R36E.

17. The method of claim 16 , wherein the recombinant FVII or FVIIa polypeptide variant comprises an amino acid substitution in position 34.

18. The method of claim 17 , wherein a negatively charged amino acid residue is substituted for the alanine residue in position 34.

19. The method of claim 18 , wherein said substitution in position 34 is A34E.

20. The method of claim 1 , wherein the recombinant FVII or FVIIa polypeptide variant comprises at least one introduced N-glycosylation site in a position located outside the Gla domain.

21. The method of claim 20 , wherein the at least one introduced N-glycosylation site comprises at least one amino acid substitution selected from the group consisting of T106N, I205T, and V253N.

22. The method of claim 4 , wherein the recombinant FVII or FVIIa polypeptide variant comprises at least one introduced N-glycosylation site in a position located outside the Gla domain.

23. The method of claim 22 , wherein the at least one introduced N-glycosylation site comprises at least one amino acid substitution selected from the group consisting of T106N, I205T, and V253N.

24. The method of claim 1 , wherein the recombinant FVII or FVIIa polypeptide variant comprises at least two introduced N-glycosylation sites selected from the group consisting of T106N, I205T, and V253N.

25. The method of claim 24 , wherein the recombinant FVII or FVIIa polypeptide variant comprises the substitutions P10Q+K32E+A34E+R36E+T106N+V253N.

26. The method of claim 24 , wherein the recombinant FVII or FVIIa polypeptide variant comprises the substitutions P10Q+K32E+A34E+R36E+T106N+I205T.

27. The method of claim 24 , wherein the recombinant FVII or FVIIa polypeptide variant comprises the substitutions P10Q+K32E+A34E+R36E+I205T+V253N.

28. The method of claim 1 , wherein the recombinant FVII or FVIIa polypeptide variant is in its activated form.

29. The method of claim 1 , wherein said disease or disorder is hemorrhage.

30. The method of claim 1 , wherein the recombinant FVII or FVIIa polypeptide variant comprises an amino acid sequence which differs from the amino acid sequence of hFVII or hFVIIa shown in SEQ ID NO: 1 in no more than 10 amino acid residues.

31. The method of claim 3 , wherein the amino acid substitution in position 36 is R36D or R36E.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2008
From: MAXYGEN HOLDINGS LTD.
To: BAYER HEALTHCARE LLC
Reel/Frame 021450/0225 →